{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T05:18:08Z","timestamp":1790918288999,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jhep.2012.11.010","type":"journal-article","created":{"date-parts":[[2012,11,21]],"date-time":"2012-11-21T09:49:15Z","timestamp":1353491355000},"page":"529-534","source":"Crossref","is-referenced-by-count":209,"title":["Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis"],"prefix":"10.1016","volume":"58","author":[{"given":"Christina","family":"Weiler-Normann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Quaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Wiegard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Glaubke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Pannicke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansgar W.","family":"Lohse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2012.11.010_b0005","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jhep.2010.12.012","article-title":"Autoimmune hepatitis","volume":"55","author":"Lohse","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0010","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1002\/hep.23840","article-title":"Treatment response in patients with autoimmune hepatitis","volume":"52","author":"Schramm","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.010_b0015","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.010_b0020","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2012.11.010_b0025","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0030","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/00042737-200504000-00012","article-title":"Promising treatment of autoimmune hepatitis with 6-thioguanine after adverse events on azathioprine","volume":"17","author":"de Boer","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0035","first-page":"571","article-title":"Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis\u2013report of three cases","volume":"35","author":"Kanzler","year":"1997","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0040","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1023\/A:1010683817344","article-title":"Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis","volume":"46","author":"Malekzadeh","year":"2001","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2012.11.010_b0045","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis","volume":"13","author":"Larsen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1055\/s-2001-13708","article-title":"Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience","volume":"39","author":"Kanzler","year":"2001","journal-title":"Z Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0175","doi-asserted-by":"crossref","DOI":"10.1002\/hep.23924","article-title":"Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis","volume":"52","author":"Muratori","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.010_b0185","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/qjmed\/hcq152","article-title":"TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future","volume":"103","author":"Karampetsou","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2012.11.010_b0065","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease","volume":"17","author":"Beigel","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.jhep.2012.11.010_b0070","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1016\/j.jaad.2009.02.029","article-title":"Autoimmune hepatitis in two psoriasis patients treated with inflixmab","volume":"63","author":"Goujon","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0075","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.meg.0000108344.41221.8b","article-title":"Increased production of granulocyte-macrophage colony-stimulating factor in Crohn\u2019s disease\u2013a possible target for infliximab treatment","volume":"16","author":"Agnholt","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0080","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.4049\/jimmunol.1200131","article-title":"Cutting edge: suppression of GM-CSF expression in murine and human T cells by IL-27","volume":"189","author":"Young","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.jhep.2012.11.010_b0085","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1172\/JCI38482","article-title":"Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans","volume":"119","author":"Bruns","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2012.11.010_b0090","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1038\/ajg.2009.433","article-title":"A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade","volume":"104","author":"Weiler-Normann","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0095","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0100","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2012.11.010_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2008-1040641","article-title":"Natural history, clinical features, and treatment of autoimmune hepatitis","volume":"4","author":"Czaja","year":"1984","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2012.11.010_b0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0120","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0125","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jhep.2011.01.012","article-title":"Role of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"55","author":"Schramm","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0130","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/01.mpg.0000235975.75120.38","article-title":"Follow-up of children with autoimmune hepatitis treated with cyclosporine","volume":"43","author":"Cuarterolo","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhep.2012.11.010_b0135","first-page":"57","article-title":"Treatment of patients with severe autoimmune hepatitis","volume":"54","author":"Larsen","year":"2008","journal-title":"Minerva Gastroenterol Dietol"},{"key":"10.1016\/j.jhep.2012.11.010_b0170","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/ajg.2011.73","article-title":"Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2012.11.010_b0145","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/qjmed\/hcq152","article-title":"TNF-alpha antagonists beyond approved indications: stories of success and prospects for the future","volume":"103","author":"Karampetsou","year":"2010","journal-title":"QJM"},{"key":"10.1016\/j.jhep.2012.11.010_b0150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/01.meg.0000108345.41221.c2","article-title":"Infliximab: mechanism of action beyond TNF-alpha neutralization in inflammatory bowel disease","volume":"16","author":"Kirman","year":"2004","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2012.11.010_b0155","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1055\/s-2008-1040319","article-title":"Bacterial infections, sepsis, and multiorgan failure in cirrhosis","volume":"28","author":"Tandon","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2012.11.010_b0160","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/lt.22018","article-title":"Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European liver transplant registry","volume":"16","author":"Schramm","year":"2010","journal-title":"Liver Transpl"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812008781?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827812008781?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T08:34:29Z","timestamp":1745224469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827812008781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0168827812008781"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2012.11.010","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}